---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-082174"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T13:15:33.782925+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Taysha reports Q4 net loss $55.7M; cash $87.9M; progress on Rett and GAN trials

## Summary
- Net loss Q4 2022: $55.7M ($0.99/shr) vs $50.4M Q4 2021; full year loss $166.0M vs $174.5M.
- Cash $87.9M at 12/31/22; expected to fund operations into Q1 2024.
- TSHA-102: screening started for REVEAL trial; first adult dosing H1 2023; initial safety data expected H1 2023.
- TSHA-120: FDA suggests alternative trial designs; formal meeting request planned Q2 2023.
- Non-cash impairment charge of $36.4M in Q4 2022 for NC manufacturing facility.

## SEC filing metadata
- accession: 0001193125-23-082174
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523082174/0001193125-23-082174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523082174/d486592d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-082174
- JSON: https://secwatch.observer/filing/0001193125-23-082174.json
- Plain text: https://secwatch.observer/filing/0001193125-23-082174.txt

## Key facts
- Earnings Releases
  Taysha Gene Therapies, Inc. reported financial results for the fourth quarter and full-year ended December 31, 2022.
  - Period: the fourth quarter and full-year ended December 31, 2022
  - Result: reported results
  source text: Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today reported financial results for the fourth quarter and full-year ended December 31, 2022, and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523082174/0001193125-23-082174-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.